Beyond pubmed: Searching the “grey literature” for clinical trial results

Innovations in Clinical Neuroscience

Volumn 11, Issue 7-8, 2014, Pages 42-46

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Clinical trial registries; Digital archives; Grey literature; Publishers; PubMed; Searching

Indexed keywords

ARTICLE; BIOMEDICINE; CLINICAL RESEARCH; GENOMICS; HEALTH SERVICE; HUMAN; INFORMATION CENTER; INFORMATION RETRIEVAL; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; PATENT; PUBLICATION;

EID: 84938084465     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Citrome L, Moss SV, Graf C. How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do. Int J Clin Pract. 2009;63(11):1565–70
2. The New York Academy of Medicine. Fourth International Conference on Grey Literature: new frontiers in grey literature. Grey Literature Network Service. Washington DC, USA, 4–5 October 1999
3. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialized second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707–18
4. Turner EH. How to access and process FDA drug approval packages for use in research. BMJ. 2013;347:f5992
5. Ohmer J, Miller JW, Sasich LD. Accessing FDA approval packages and briefing documents. AnnPharmacother. 2007;41(12):2071–2
6. Sasich LD, Sukkari SR, Cook GE, Tuttle DA. The importance of FDA approval packages and briefing documents in pharmacy education. Am J Pharm Educ. 2009;73(7):126
7. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599–613
8. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229–37.